Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Hematopoietic Malignancies
Solid Tumor
0 Years and older, Male and Female
208750 (primary)
NCI-2018-01288
ADP-0000-002
Summary
This trial will evaluate long term safety of participants who have received GlaxoSmithKline
(GSK) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Objectives
Participants who received a GSK adoptive cell therapy will be enrolled in this
non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for up
to 15 years post-infusion of lentiviral vector-based adoptive cell therapy. Participants will
be monitored for safety following last adoptive cell therapy infusion.
Eligibility
- Participants who have received at least one dose of GSK adoptive cell therapy agent.
- Participants who have completed GSK sponsored or supported interventional study or have withdrawn from it.
- Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- The investigator is responsible for review of medical history.
- Capable of giving signed informed consent.
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.